The GLP-1 agonists market is set to skyrocket, reaching USD 170.75 billion by 2033, growing from USD 64.42 billion in 2025 at ...

Expanded use of GLP-1 drugs may lead to more side effects, already the subject of thousands of lawsuits now moving through ...

A recent study found that Glucagon-like peptide-1 (GLP-1) receptor agonist use in hypertrophic cardiomyopathy (HCM) patients ...

GLP-1 agonists are pivotal in obesity care, promoting weight loss and addressing related health issues, with a focus on ...

Danish pharmaceutical manufacturer Novo Nordisk on Dec. 22 announced that the U.S. Food and Drug Administration (FDA) has ...

A systematic review and meta-analysis evaluated the risk for obesity-related cancer associated with glucagon-like peptide-1 receptor agonists (GLP-1RAs) in patients with type 2 diabetes (T2D) or ...

GLP-1 agonists like Ozempic are primarily used to treat type 2 diabetes. Its popularity has even influenced wholesale retailer Costco to sell Ozempic and Wegovy (another popular semaglutide) at its ...

Meanwhile, people with overweight or obesity lost up to 11.3% more weight than placebo by week 36 with a novel GLP-1 agonist ...

Glucagon-like peptide 1 receptor agonists (GLP-1 RAs) may protect against vertebral fractures in people with diabetes, ...

Research last month suggested that starting GLP-1 receptor agonist treatment in people with epilepsy and type 2 diabetes was associated with reduced risks of seizure recurrence, hospitalization, and ...

LEXX READ THE FULL LEXX RESEARCH REPORT Lexaria Bioscience Corporation (NASDAQ:LEXX) announced results from its Phase Ib ...

Type 2 diabetes is a recognized risk factor for vertebral fractures, which can lead to long-term disability and increased ...